Beaufort Securities Reiterates “Speculative Buy” Rating for Tissue Regenix Group PLC (TRX)
Tissue Regenix Group PLC (LON:TRX)‘s stock had its “speculative buy” rating reissued by stock analysts at Beaufort Securities in a research note issued to investors on Monday.
Tissue Regenix Group PLC (TRX) remained flat at GBX 14.25 on Monday. 110,482 shares of the stock were exchanged. Tissue Regenix Group PLC has a 52 week low of GBX 14.00 and a 52 week high of GBX 21.55. The stock’s market capitalization is GBX 105.90 million. The stock has a 50-day moving average price of GBX 15.39 and a 200 day moving average price of GBX 17.65.
TRADEMARK VIOLATION NOTICE: This news story was originally published by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/06/05/beaufort-securities-reiterates-speculative-buy-rating-for-tissue-regenix-group-plc-trx.html.
Tissue Regenix Group PLC Company Profile
Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient’s body.
Receive News & Ratings for Tissue Regenix Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tissue Regenix Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.